Clinical Trial Update: Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis [Phase 3]

View source ↗

Summary

Phase 3 safety and effectiveness study of RP103 (cysteamine bitartrate delayed-release capsules) in cystinosis patients has completed and results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• RP103 (cysteamine bitartrate delayed-release capsules) (cysteamine bitartrate delayed-release)

Snippet

Sponsor: Amgen | Conditions: Cystinosis | Phase 3 | Status: COMPLETED | Results posted: 2018-01-16